Unichem Labs anticonvulsant drug Carbamazepine gets USFDA okay

Carbamazepine Tablets are indicated for use as an anticonvulsant drug and in the treatment of the pain associated with true trigeminal neuralgia.

Published On 2022-08-23 07:02 GMT   |   Update On 2022-08-23 07:04 GMT

Mumbai: Drugmaker, Unichem Laboratories Limited, has recently announced that the company has received Abbreviated New Drug Application (ANDA) approval for its Carbamazepine Tablets USP, 200 mg from the United States Food and Drug Administration (USFDA).The medicine is a generic version of TEGRETOL (Carbamazepine) Tablet, 200 mg of Novartis Pharmaceuticals Corp. Carbamazepine Tablets...

Login or Register to read the full article

Mumbai: Drugmaker, Unichem Laboratories Limited, has recently announced that the company has received Abbreviated New Drug Application (ANDA) approval for its Carbamazepine Tablets USP, 200 mg from the United States Food and Drug Administration (USFDA).

The medicine is a generic version of TEGRETOL (Carbamazepine) Tablet, 200 mg of Novartis Pharmaceuticals Corp.
Carbamazepine Tablets are indicated for use as an anticonvulsant drug and in the treatment of the pain associated with true trigeminal neuralgia. The product will be commercialized from Unichem's Goa Plant.

Unichem Laboratories Limited is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. 

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News